GenetaStix Overview

  • Founded
  • 2000
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

GenetaStix General Information


Producer of antibody therapeutics. The company engages itself in the production of human monoclonal antibody therapeutics to fight cancer, infectious and autoimmune diseases and other life threatening and debilitating diseases.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Therapeutic Devices
Primary Office
  • 780 Montague Expressway
  • Suite 303
  • San Jose, CA
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

GenetaStix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 26-Jul-2007 00.00 Completed Generating Revenue
1. Early Stage VC (Series A) 09-Nov-2000 00.00 00.00 00.000 Completed Startup
To view GenetaStix’s complete valuation and funding history, request access »

GenetaStix Cap Table

Stock # of Shares
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view GenetaStix’s complete cap table history, request access »

GenetaStix Executive Team (2)

Name Title Board Seat Contact Info
Li Zhu Ph.D Chief Executive Officer, President, Lead Scientist Board Member & Co-Founder
S. Benjamin Hua Ph.D Vice President, Research & Co-Founder
To view GenetaStix’s complete executive team members history, request access »

GenetaStix Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Fortune Venture Investment Group Venture Capital Minority 000 0000 000000 0
Kenson Ventures Venture Capital Minority 000 0000 000000 0
To view GenetaStix’s complete investors history, request access »